---
title: 'Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic
  Regimen: A Nonrandomized Controlled Trial'
date: '2023-10-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37883081/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231026180915&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS AND RELEVANCE: This feasible and well-tolerated MEMMAT combination
  regimen demonstrated promising activity in patients with previously irradiated recurrent
  medulloblastoma. Given these results, this predominantly oral, well-tolerated, and
  outpatient treatment warrants further ...'
disable_comments: true
---
CONCLUSIONS AND RELEVANCE: This feasible and well-tolerated MEMMAT combination regimen demonstrated promising activity in patients with previously irradiated recurrent medulloblastoma. Given these results, this predominantly oral, well-tolerated, and outpatient treatment warrants further ...